 |
|
Evaluation of New Treatments in Radiation Oncology
Are They Better Than Standard Treatments?
Heloisa P. Soares, MD;
Ambuj Kumar, MD, MPH;
Stephanie Daniels, RN, MPH;
Suzanne Swann, PhD;
Alan Cantor, PhD;
Iztok Hozo, PhD;
Mike Clark, DPhil;
Fadila Serdarevic, MD, MPH;
Clement Gwede, RN, PhD;
Andy Trotti, MD;
Benjamin Djulbegovic, MD, PhD
JAMA. 2005;293:970-978.
Context The superiority of innovative over standard treatments is not known. To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention.
Objective To determine the success rate of innovative treatments by assessing preferences between experimental and standard treatments according to original investigators’ conclusions, determining the proportion of RCTs that achieved primary outcomes’ statistical significance, and performing meta-analysis to examine if the summary point estimate favored innovative vs standard treatments.
Data Sources Randomized controlled trials conducted by the Radiation Therapy Oncology Group (RTOG).
Study Selection All completed phase 3 trials conducted by the RTOG since its creation in 1968 until 2002. For multiple publications of the same study, we used the one with the most complete primary outcomes and with the longest follow-up information.
Data Extraction We used the US National Cancer Institute definition of completed studies to determine the publication rate. We extracted data related to publication status, methodological quality, and treatment comparisons. One investigator extracted the data from all studies and 2 independent investigators extracted randomly about 50% of the data. Disagreements were resolved by consensus during a meeting.
Data Synthesis Data on 12 734 patients from 57 trials were evaluated. The publication rate was 95%. The quality of trials was high. We found no evidence of inappropriateness of the choice of comparator. Although the investigators judged that standard treatments were preferred in 71% of the comparisons, when data were meta-analyzed innovations were as likely as standard treatments to be successful (odds ratio for survival, 1.01; 99% confidence interval, 0.96-1.07; P = .5). In contrast, treatment-related mortality was worse with innovations (odds ratio, 1.76; 99% confidence interval, 1.01-3.07; P = .008). We found no predictable pattern of treatment successes in oncology: sometimes innovative treatments are better than the standard ones and vice versa; in most cases there were no substantive differences between experimental and conventional treatments.
Conclusion The finding that the results in individual trials cannot be predicted in advance indicates that the system and rationale for RCTs is well preserved and that successful interventions can only be identified after an RCT is completed.
Author Affiliations: H. Lee Moffitt Cancer Center & Research Institute at University of South Florida, Tampa (Drs Soares, Kumar, Cantor, Serdarevic, Gwede, Trotti, and Djulbegovic and Ms Daniels); Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pa (Dr Swann); Department of Mathematics, University of Indiana Northwest, Gary (Dr Hozo); UK Cochrane Centre, Oxford, England (Dr Clark).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
The Case for Randomized Trials in Cancer Treatment: New Is Not Always Better
and
JAMA. ;293():1001-1003.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment Success in Cancer: New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Institute-Sponsored Cooperative Oncology Groups, 1955 to 2006
Djulbegovic et al.
Arch Intern Med 2008;168:632-642.
ABSTRACT
| FULL TEXT
Technology Assessment in Radiology: Putting the Evidence in Evidence-based Radiology
Hollingworth and Jarvik
Radiology 2007;244:31-38.
ABSTRACT
| FULL TEXT
Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Institute-Sponsored Cooperative Groups
Kumar et al.
JCO 2007;25:1272-1276.
ABSTRACT
| FULL TEXT
Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group
Kumar et al.
BMJ 2005;331:1295.
ABSTRACT
| FULL TEXT
The Case for Randomized Trials in Cancer Treatment: New Is Not Always Better
Grann and Grann
JAMA 2005;293:1001-1003.
FULL TEXT
|
